Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Methamphetamine | 24 | 2021 | 132 | 8.540 |
Why?
|
| Oxytocin | 10 | 2020 | 124 | 4.320 |
Why?
|
| Drug-Seeking Behavior | 14 | 2021 | 213 | 3.840 |
Why?
|
| Dopamine Uptake Inhibitors | 10 | 2018 | 152 | 2.900 |
Why?
|
| Self Administration | 26 | 2020 | 419 | 2.860 |
Why?
|
| Cocaine | 14 | 2018 | 555 | 2.760 |
Why?
|
| Central Nervous System Stimulants | 11 | 2019 | 221 | 2.620 |
Why?
|
| Cues | 12 | 2021 | 654 | 2.440 |
Why?
|
| Empathy | 4 | 2022 | 45 | 2.400 |
Why?
|
| Rats | 43 | 2022 | 5300 | 2.180 |
Why?
|
| Rats, Sprague-Dawley | 34 | 2021 | 2083 | 2.140 |
Why?
|
| Behavior, Animal | 12 | 2021 | 470 | 2.100 |
Why?
|
| Extinction, Psychological | 12 | 2020 | 240 | 2.040 |
Why?
|
| Cocaine-Related Disorders | 8 | 2018 | 504 | 2.030 |
Why?
|
| Memory Disorders | 6 | 2018 | 111 | 1.970 |
Why?
|
| Nucleus Accumbens | 8 | 2021 | 417 | 1.950 |
Why?
|
| Amphetamine-Related Disorders | 9 | 2019 | 92 | 1.910 |
Why?
|
| Behavior, Addictive | 5 | 2022 | 317 | 1.760 |
Why?
|
| Animals | 57 | 2022 | 20881 | 1.600 |
Why?
|
| Exploratory Behavior | 4 | 2015 | 79 | 1.590 |
Why?
|
| Conditioning, Operant | 9 | 2019 | 241 | 1.370 |
Why?
|
| Glutamic Acid | 7 | 2019 | 332 | 1.300 |
Why?
|
| Prefrontal Cortex | 7 | 2021 | 640 | 1.250 |
Why?
|
| Benzhydryl Compounds | 3 | 2013 | 62 | 1.160 |
Why?
|
| Perirhinal Cortex | 2 | 2018 | 5 | 1.160 |
Why?
|
| Disease Models, Animal | 8 | 2018 | 2550 | 1.140 |
Why?
|
| Receptors, Metabotropic Glutamate | 4 | 2017 | 75 | 1.110 |
Why?
|
| Conditioning, Classical | 6 | 2017 | 57 | 1.000 |
Why?
|
| Substance-Related Disorders | 4 | 2022 | 1242 | 0.990 |
Why?
|
| Male | 47 | 2022 | 37321 | 0.950 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 4 | 2019 | 266 | 0.860 |
Why?
|
| Heroin | 2 | 2020 | 49 | 0.840 |
Why?
|
| Helping Behavior | 1 | 2022 | 4 | 0.820 |
Why?
|
| Rats, Long-Evans | 9 | 2016 | 203 | 0.820 |
Why?
|
| Nicotine | 4 | 2010 | 350 | 0.810 |
Why?
|
| Reward | 5 | 2019 | 201 | 0.810 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2021 | 5 | 0.790 |
Why?
|
| Bupropion | 4 | 2008 | 63 | 0.760 |
Why?
|
| Models, Animal | 1 | 2021 | 252 | 0.700 |
Why?
|
| Heroin Dependence | 1 | 2020 | 23 | 0.700 |
Why?
|
| Restraint, Physical | 1 | 2020 | 59 | 0.690 |
Why?
|
| Brain | 4 | 2022 | 2176 | 0.690 |
Why?
|
| Corpus Striatum | 5 | 2012 | 279 | 0.680 |
Why?
|
| Receptors, Oxytocin | 1 | 2018 | 9 | 0.640 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2016 | 1745 | 0.640 |
Why?
|
| Models, Psychological | 1 | 2019 | 180 | 0.640 |
Why?
|
| Genetic Techniques | 1 | 2018 | 32 | 0.630 |
Why?
|
| Synapses | 3 | 2019 | 222 | 0.630 |
Why?
|
| Neuronal Plasticity | 1 | 2021 | 274 | 0.620 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 2 | 2015 | 51 | 0.600 |
Why?
|
| Nicotinic Agonists | 2 | 2010 | 111 | 0.590 |
Why?
|
| Central Nervous System Agents | 1 | 2017 | 37 | 0.580 |
Why?
|
| Excitatory Postsynaptic Potentials | 2 | 2017 | 87 | 0.580 |
Why?
|
| Social Behavior | 1 | 2018 | 164 | 0.580 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2017 | 114 | 0.580 |
Why?
|
| Habits | 1 | 2016 | 14 | 0.550 |
Why?
|
| Locomotion | 2 | 2019 | 135 | 0.540 |
Why?
|
| Goals | 1 | 2016 | 65 | 0.530 |
Why?
|
| Motivation | 5 | 2016 | 561 | 0.520 |
Why?
|
| Mental Disorders | 1 | 2021 | 659 | 0.510 |
Why?
|
| Dietary Sucrose | 1 | 2015 | 18 | 0.500 |
Why?
|
| Long-Term Synaptic Depression | 1 | 2015 | 32 | 0.490 |
Why?
|
| Psychotropic Drugs | 1 | 2015 | 83 | 0.480 |
Why?
|
| Eating | 1 | 2015 | 119 | 0.470 |
Why?
|
| Discrimination Learning | 3 | 2010 | 45 | 0.470 |
Why?
|
| Stress, Psychological | 1 | 2020 | 824 | 0.450 |
Why?
|
| Motor Activity | 6 | 2015 | 621 | 0.440 |
Why?
|
| Cognition | 2 | 2016 | 513 | 0.430 |
Why?
|
| Cystine | 1 | 2012 | 20 | 0.400 |
Why?
|
| Sucrose | 3 | 2008 | 58 | 0.390 |
Why?
|
| Recurrence | 4 | 2018 | 948 | 0.380 |
Why?
|
| Sex Characteristics | 4 | 2019 | 295 | 0.380 |
Why?
|
| Acetylcysteine | 2 | 2011 | 296 | 0.370 |
Why?
|
| Emotions | 2 | 2022 | 244 | 0.370 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 3 | 2011 | 82 | 0.360 |
Why?
|
| Isoxazoles | 1 | 2010 | 22 | 0.350 |
Why?
|
| Pyrrolidines | 1 | 2010 | 45 | 0.350 |
Why?
|
| Quinoxalines | 1 | 2010 | 78 | 0.340 |
Why?
|
| Female | 13 | 2021 | 38074 | 0.340 |
Why?
|
| Benzazepines | 1 | 2010 | 104 | 0.340 |
Why?
|
| Analysis of Variance | 5 | 2016 | 1040 | 0.340 |
Why?
|
| Memory | 1 | 2010 | 214 | 0.330 |
Why?
|
| Cognition Disorders | 1 | 2012 | 342 | 0.330 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 1293 | 0.320 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2011 | 435 | 0.310 |
Why?
|
| Nicotinic Antagonists | 1 | 2007 | 11 | 0.300 |
Why?
|
| Odorants | 2 | 2020 | 52 | 0.300 |
Why?
|
| Appetite | 1 | 2006 | 16 | 0.290 |
Why?
|
| Brain Mapping | 2 | 2022 | 532 | 0.270 |
Why?
|
| Chlorides | 1 | 2006 | 68 | 0.270 |
Why?
|
| Time Factors | 6 | 2016 | 4655 | 0.260 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2007 | 189 | 0.250 |
Why?
|
| Altruism | 1 | 2022 | 24 | 0.210 |
Why?
|
| Hypothalamus | 1 | 2022 | 78 | 0.210 |
Why?
|
| Cerebral Cortex | 3 | 2017 | 415 | 0.200 |
Why?
|
| Tissue Culture Techniques | 3 | 2019 | 62 | 0.200 |
Why?
|
| Hallucinogens | 1 | 2022 | 14 | 0.200 |
Why?
|
| Cannabidiol | 1 | 2022 | 31 | 0.200 |
Why?
|
| Receptors, Dopamine D2 | 3 | 2007 | 109 | 0.190 |
Why?
|
| Cannabinoids | 1 | 2022 | 90 | 0.190 |
Why?
|
| Synaptic Transmission | 3 | 2017 | 236 | 0.190 |
Why?
|
| Infusions, Intraventricular | 2 | 2017 | 8 | 0.190 |
Why?
|
| Piperazines | 2 | 2015 | 206 | 0.180 |
Why?
|
| Sex Factors | 2 | 2016 | 1266 | 0.180 |
Why?
|
| Cannabis | 1 | 2022 | 115 | 0.180 |
Why?
|
| Vagus Nerve | 1 | 2020 | 90 | 0.170 |
Why?
|
| Long-Term Potentiation | 2 | 2010 | 53 | 0.170 |
Why?
|
| Administration, Intravenous | 2 | 2016 | 89 | 0.170 |
Why?
|
| Opioid Peptides | 1 | 2019 | 17 | 0.170 |
Why?
|
| Reaction Time | 1 | 2019 | 170 | 0.170 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2019 | 37 | 0.160 |
Why?
|
| Progesterone | 1 | 2019 | 115 | 0.160 |
Why?
|
| Random Allocation | 1 | 2020 | 442 | 0.160 |
Why?
|
| Estradiol | 1 | 2019 | 176 | 0.160 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2011 | 92 | 0.150 |
Why?
|
| Spatial Behavior | 1 | 2017 | 18 | 0.150 |
Why?
|
| Analgesics | 1 | 2019 | 118 | 0.150 |
Why?
|
| Hippocampus | 2 | 2011 | 471 | 0.150 |
Why?
|
| Signal Transduction | 2 | 2021 | 2689 | 0.150 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2017 | 128 | 0.140 |
Why?
|
| Lithium Chloride | 1 | 2016 | 10 | 0.140 |
Why?
|
| Isoflurane | 1 | 2016 | 16 | 0.140 |
Why?
|
| Anesthetics, Inhalation | 1 | 2016 | 21 | 0.140 |
Why?
|
| Methylphenidate | 2 | 2007 | 97 | 0.130 |
Why?
|
| Lisuride | 2 | 2006 | 3 | 0.130 |
Why?
|
| Pain | 1 | 2019 | 472 | 0.130 |
Why?
|
| Repetition Priming | 1 | 2015 | 2 | 0.130 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2015 | 20 | 0.130 |
Why?
|
| Cycloserine | 1 | 2015 | 30 | 0.120 |
Why?
|
| Appetitive Behavior | 1 | 2015 | 18 | 0.120 |
Why?
|
| Phenols | 1 | 2015 | 73 | 0.120 |
Why?
|
| Piperidines | 1 | 2015 | 123 | 0.120 |
Why?
|
| Cerebrovascular Circulation | 1 | 2016 | 296 | 0.120 |
Why?
|
| Dopamine | 2 | 2008 | 474 | 0.120 |
Why?
|
| Oxygen | 1 | 2016 | 386 | 0.120 |
Why?
|
| Estrous Cycle | 1 | 2013 | 23 | 0.110 |
Why?
|
| Humans | 5 | 2022 | 68618 | 0.110 |
Why?
|
| Homeostasis | 2 | 2011 | 291 | 0.100 |
Why?
|
| Secondary Prevention | 2 | 2010 | 291 | 0.100 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2011 | 21 | 0.100 |
Why?
|
| Neurons | 1 | 2017 | 881 | 0.100 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2011 | 51 | 0.100 |
Why?
|
| Drug Interactions | 1 | 2012 | 289 | 0.100 |
Why?
|
| Allosteric Regulation | 1 | 2010 | 58 | 0.090 |
Why?
|
| Mice | 2 | 2021 | 8474 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 567 | 0.090 |
Why?
|
| Choice Behavior | 1 | 2010 | 85 | 0.090 |
Why?
|
| Varenicline | 1 | 2010 | 98 | 0.080 |
Why?
|
| Dopamine Agonists | 2 | 2008 | 68 | 0.080 |
Why?
|
| Haptens | 1 | 2009 | 11 | 0.080 |
Why?
|
| Vaccines, Subunit | 1 | 2009 | 10 | 0.080 |
Why?
|
| Ligands | 1 | 2010 | 317 | 0.080 |
Why?
|
| Hypoxia, Brain | 1 | 2008 | 16 | 0.080 |
Why?
|
| Dopamine Antagonists | 2 | 2006 | 65 | 0.080 |
Why?
|
| Animals, Newborn | 2 | 2006 | 396 | 0.080 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2007 | 14 | 0.080 |
Why?
|
| Propylamines | 1 | 2007 | 22 | 0.080 |
Why?
|
| Naloxone | 1 | 2007 | 56 | 0.070 |
Why?
|
| Amphetamine | 2 | 2005 | 77 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 2223 | 0.070 |
Why?
|
| Body Weight | 2 | 2006 | 554 | 0.070 |
Why?
|
| Sweetening Agents | 1 | 2006 | 23 | 0.070 |
Why?
|
| Weaning | 1 | 2006 | 12 | 0.070 |
Why?
|
| Manganese Compounds | 1 | 2006 | 8 | 0.070 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2005 | 87 | 0.060 |
Why?
|
| Binding Sites | 1 | 2006 | 631 | 0.060 |
Why?
|
| Patch-Clamp Techniques | 2 | 2017 | 204 | 0.060 |
Why?
|
| Putamen | 1 | 2004 | 35 | 0.060 |
Why?
|
| Caudate Nucleus | 1 | 2004 | 56 | 0.060 |
Why?
|
| Iron | 1 | 2006 | 197 | 0.060 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2022 | 20 | 0.050 |
Why?
|
| Dronabinol | 1 | 2022 | 84 | 0.050 |
Why?
|
| Menstrual Cycle | 1 | 2019 | 64 | 0.040 |
Why?
|
| Synaptic Potentials | 1 | 2019 | 8 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2019 | 371 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 411 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 2 | 2010 | 89 | 0.040 |
Why?
|
| Pyramidal Cells | 1 | 2017 | 79 | 0.040 |
Why?
|
| Microinjections | 1 | 2016 | 130 | 0.030 |
Why?
|
| Dopamine D2 Receptor Antagonists | 2 | 2006 | 13 | 0.030 |
Why?
|
| Thiazoles | 1 | 2015 | 95 | 0.030 |
Why?
|
| Sympathomimetics | 1 | 2012 | 16 | 0.030 |
Why?
|
| Microdialysis | 1 | 2010 | 147 | 0.020 |
Why?
|
| Reference Standards | 1 | 2010 | 115 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 381 | 0.020 |
Why?
|
| Complement C5a | 1 | 2009 | 15 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2009 | 63 | 0.020 |
Why?
|
| Convulsants | 1 | 2008 | 4 | 0.020 |
Why?
|
| Nitro Compounds | 1 | 2008 | 11 | 0.020 |
Why?
|
| Propionates | 1 | 2008 | 21 | 0.020 |
Why?
|
| Neurotoxins | 1 | 2008 | 30 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2008 | 104 | 0.020 |
Why?
|
| Species Specificity | 1 | 2008 | 303 | 0.020 |
Why?
|
| Antibodies | 1 | 2009 | 241 | 0.020 |
Why?
|
| Movement | 1 | 2008 | 179 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2008 | 447 | 0.020 |
Why?
|
| Association Learning | 1 | 2007 | 36 | 0.020 |
Why?
|
| Neostriatum | 1 | 2007 | 60 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2009 | 483 | 0.020 |
Why?
|
| Morphine | 1 | 2007 | 76 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2008 | 324 | 0.020 |
Why?
|
| alpha-Methyltyrosine | 1 | 2006 | 6 | 0.020 |
Why?
|
| Reserpine | 1 | 2006 | 24 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2008 | 682 | 0.020 |
Why?
|
| Methyltyrosines | 1 | 2004 | 6 | 0.020 |
Why?
|
| Hyperkinesis | 1 | 2004 | 8 | 0.020 |
Why?
|
| Apomorphine | 1 | 2004 | 48 | 0.020 |
Why?
|
| Dextroamphetamine | 1 | 2004 | 30 | 0.020 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2004 | 71 | 0.020 |
Why?
|
| Amino Acid Transport System X-AG | 1 | 2004 | 11 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 2004 | 57 | 0.010 |
Why?
|
| Membrane Transport Proteins | 1 | 2004 | 81 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 659 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 290 | 0.010 |
Why?
|
| Age Factors | 1 | 2007 | 1864 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 370 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1174 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2005 | 1692 | 0.010 |
Why?
|